Alprazolam in Panic Disorder and Agoraphobia: Results From a Multicenter Trial: III. Discontinuation Effects
The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
Preliminary reports of discontinuation of alprazolam therapy in patients with panic disorder have revealed worsening of symptoms despite gradual withdrawal of medication. In this study, 126 patients with panic disorder and phobic avoidance received either alprazolam or placebo in doses of 2 to 10 mg daily for eight weeks. The medication was tapered over a period of four weeks, and patients were observed for another two weeks after all medication was discontinued. Sixty of the 63 alprazolam-treated patients and 49 of the 63 placebo-treated patients entered the taper and discontinuation study. After improvement in the active treatment period, the alprazolam-treated group had significant relapse between the first and last week of taper. However, during the second postdiscontinuation week, outcome scores were not significantly different from those of the placebo-treated group who did not deteriorate during taper. Twenty-seven percent of the alprazolam-treated group reported a rebound of panic attacks during taper and 13% reported a rebound of anxiety on the Hamilton Anxiety Scale. No serious or life-threatening withdrawal symptoms were reported, but distinct, transient, mild to moderate withdrawal syndrome occurred in 35% of the alprazolam-treated group and in none of the placebo-treated group. The coexistence of symptom rebound and a withdrawal syndrome occurred in 10% of the alprazolam-treated group, but both subsided by the end of the second week without alprazolam. We recommend that patients with panic disorder be treated for a longer period, at least six months, and that medication be tapered over a more prolonged period, at least eight weeks, especially where high doses are employed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study reported that of 126 patients with panic disorder treated with alprazolam, 27% of patients had rebound anxiety that was more severe than pretreatment anxiety, and 35% of patients had new somatic symptoms after alprazolam discontinuation, despite a taper over 4 weeks (Pecknold et al., 1988).”
From A Review of Alprazolam Use, Misuse, and Withdrawal (2018) · cites this paper as Pecknold et al., 1988
Citations
Cites
Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites
Robins, L. N. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790210031005 · Cited by 2,550
Brief standard self-rating for phobic patients
Marks, I. M., & Mathews, A. M. (1979) · Behaviour Research and Therapy · doi:10.1016/0005-7967(79)90041-x · Cited by 1,801
Ballenger, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290027004 · Cited by 564
Self-citationWithdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Withdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367
Treatment of Phobias: I. Comparison of Imipramine Hydrochloride and Placebo
Zitrin, C. M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790020019002 · Cited by 342
Withdrawal reactions from chlordiazepoxide (?Librium?)
Hollister, L. E., Motzenbecker, F. P., & Degan, R. O. (1961) · Psychopharmacologia · doi:10.1007/bf00429621 · Cited by 340
Treatment of Agoraphobia With Group Exposure In Vivo and Imipramine
Zitrin, C. M. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140065007 · Cited by 332
Agoraphobia With Panic Attacks: Development, Diagnostic Stability, and Course of Illness
Breier, A. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800110015003 · Cited by 304
(1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.8.1030 · Cited by 301
Cited by
Suicidal Ideation and Suicide Attempts in Panic Disorder and Attacks
Weissman, M. M., Klerman, G. L., Markowitz, J. S., & Ouellette, R. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911023211801 · Cited by 604
Guidelines for the Rational Use of Benzodiazepines: When and What to Use
Ashton, H. (1994) · Drugs · doi:10.2165/00003495-199448010-00004 · Cited by 593
Ballenger, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290027004 · Cited by 564
Self-citationA meta-analysis of treatment outcome for panic disorder
Gould, R. A., Ott, M. W., & Pollack, M. H. (1995) · Clinical Psychology Review · doi:10.1016/0272-7358(95)00048-8 · Cited by 520
Marks, I. M., Swinson, R. P., Başoǧlu, M., Kuch, K., Noshirvani, H., O'Sullivan, G., Lelliott, P. T., Kirby, M., McNamee, G., Sengun, S., et al. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.6.776 · Cited by 478
Metadata
- Authors
- Pecknold, J. C.
- Affiliations
- McGill University (CA)
- Corresponding author
- Pecknold, John C.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1988-05-01
- Volume
- 45
- Issue
- 5
- Pages
- 429
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2063100289
- Cited by
- 204
- References
- 82
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 3 · 2022: 1 · 2020: 2 · 2019: 5 · 2017: 4 · 2016: 1 · 2015: 3 · 2013: 1 · 2012: 2
- FWCI
- 34.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- alprazolam, panic disorder, agoraphobia, benzodiazepines, medication tapering, drug discontinuation, withdrawal syndrome, relapse, phobic avoidance, treatment duration
- MeSH terms
- Adult, Alprazolam, Anxiety Disorders, Clinical Trials as Topic, Drug Administration Schedule, Fear, Female, Humans, Male, Outcome and Process Assessment, Health Care, Panic, Personality Inventory, Placebos, Psychiatric Status Rating Scales, Recurrence, Substance Withdrawal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alprazolam in Panic Disorder and Agoraphobia: Results From a Multicenter Trial: III. Discontinuation Effects. https://app.cochat.ai/papers/10.1001/archpsyc.1988.01800290043006
- The paper
- Pecknold, J. C. (1988). Alprazolam in Panic Disorder and Agoraphobia: Results From a Multicenter Trial: III. Discontinuation Effects. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1988.01800290043006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.